Evotec Completes Acquisition of DeveloGen

Evotec Completes Acquisition of DeveloGen

Hamburg, Germany, Sep 02, 2010 (Thomson Reuters ONE via COMTEX) -- Evotec AG / Evotec Completes Acquisition of DeveloGen processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.

Hamburg, Germany - 2 September 2010: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced the Closing of the agreement to acquire DeveloGen as announced in detail on 14 July 2010.

Following the successful fulfilment of various Closing conditions, the sellers of 99.3% of the shares in DeveloGen AG today transferred their shares to Evotec AG. Evotec AG issues 6,750,014 new Evotec Shares from its authorized capital as part consideration for the transaction. Following the registration of these shares at the trade register, Evotec's issued share capital will increase to EUR115,588,729.

The transaction adds two complementary alliances - one with Boehringer Ingelheim and one with Andromeda (Teva) - to Evotec's portfolio of core assets. In addition, it augments and complements Evotec's high-end drug discovery platform and capability with DeveloGen's target discovery, validation and in vivo/in vitro pharmacology expertise and adds core disease biology know-how in metabolic diseases and endocrine disorders. These skills further enhance Evotec's ability to deliver high quality, innovative solutions to its partners on a global scale.

Contact: Dr Werner Lanthaler, Chief Executive Officer,

Evotec AG, Tel.: +49.(0)40.56081-242, [email protected]

Forward-Looking Statements - Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about our 2010 financial outlook and our expected financial results in future quarters, our revised revenue guidance for 2010 and expected revenue growth, our ability to deliver on our liquidity guidance, our belief that we are on course to sustainable profitability latest in 2012, our expectations and assumptions concerning regulatory, clinical and business strategies, the progress of our clinical development programmes and timing of the commencement and results of our clinical trials, strategic collaborations and management's plans, objectives and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured; the risk that we will not achieve the anticipated benefits of our collaborations, partnerships and acquisitions in the timeframes expected, or at all; risks relating to our ability to advance the development of product candidates currently in the pipeline or in clinical trials; our inability to further identify, develop and achieve commercial success for new products and technologies; the risk that competing products may be more successful; our inability to interest potential partners in our technologies and products; our inability to achieve commercial success for our products and technologies; our inability to protect our intellectual property and the cost of enforcing or defending our intellectual property rights; our failure to comply with regulations relating to our products and product candidates, including FDA requirements; the risk that the FDA may interpret the results of our studies differently than we have; the risk that clinical trials may not result in marketable products; the risk that we may be unable to successfully secure regulatory approval of and market our drug candidates; and risks of new, changing and competitive technologies and regulations in the U.S. and internationally.

The list of risks above is not exhaustive. Our most recent Annual Report on Form 20-F, filed with the Securities and Exchange Commission, and other documents filed with, or furnished to the Securities and Exchange Commission, contain additional factors that could impact our businesses and financial performance. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

HUG#1442123

Pdf of Press Release

--- End of Message ---

Evotec AG

Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;

Listed: Freiverkehr in Borse Stuttgart,

Freiverkehr in Hanseatische Wertpapierborse zu Hamburg,

Freiverkehr in Borse Berlin,

Freiverkehr in Borse Dusseldorf,

Freiverkehr in Bayerische Borse Munchen,

Freiverkehr in Niedersachsische Borse zu Hannover,

Prime Standard in Frankfurter Wertpapierborse,

Regulierter Markt in Frankfurter Wertpapierborse;

thomsonreuters.com

 


Copyright (C) 2010 Thomson Reuters ONE. All rights reserved.

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.